This story has been corrected to reflect that OVA1 is a risk assessment test, not a rule-out test. Also, Vermillion shifted to a focus on OVA1's negative predictive value in 2016, and the list price of CA125 is around $200. We apologize for the errors.

NEW YORK (360Dx) –Vermillion is eyeing 2019 as a breakout year for its OVA1 ovarian cancer test, as the company continues piecing together the pricing, payor, and publication elements it hopes will lay the ground work for a successful renewed sales push.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.